Don’t invest unless you’re prepared to lose all the money you invest. This is a high-risk investment and you are unlikely to be protected if something goes wrong. Take 2 mins to learn more.
alt text
Tissue Regenix Group Ltd
Company Name:Tissue Regenix Group Ltd Minimum fundraise:£0.00* High Share Price Bid:£0.00
Business Sector:Pharmaceuticals, healthcare and biotechnology Total Funds Bid to Date:£0.00 Low Share Price Bid:£0.00
Auction period:07 Jan 2026 - 24 Feb 2026 Indicative Share Price:0.40 Average Share Price Bid:£0.00**
*The company will accept oversubscription.
**In the event of significant oversubscription, shares will be allocated to bids at the average price and above.
NOTE: ASSET MATCH HAS NEGOTIATED AN “ASSET MATCH INVESTOR BONUS” FOR INVESTORS IN THIS TRANSACTION. SEE THE “OVERVIEW” SECTION BELOW FOR DETAILS.

Need help?
+44 (0) 207 248 2788

back

Tissue Regenix Group Ltd

Tissue Regenix Group Ltd

Market Cap: £3,262,920 Auction period: 07 Jan 2026 - 24 Feb 2026 Indicative price: 0.40

Live Started 47 days ago

Current Indicative Price 0.40p

Auction closes in 16 Hours


BUY ORDERS SELL ORDERS

BuyersShares Wanted Total Wanted Share Price (p)
1 50,000,000 50,105,773 0.10
-- -- 105,773 0.20
1 105,773 105,773 0.40
-- -- -- 0.50
       
Share Price (p) Total Offered Shares OfferedSellers
0.10 59,773 59,773 6
0.20 85,773 26,000 1
0.40 113,144 27,371 2
0.50 173,144 60,000 2
       

BUY ORDERS

SELL ORDERS

Buyers Shares Total Shares Share Price (p) Total Shares Shares Sellers
1 50,000,000 50,105,773 0.10 59,773 59,773 6
-- -- 105,773 0.20 85,773 26,000 1
1 105,773 105,773 0.40 113,144 27,371 2
-- -- -- 0.50 173,144 60,000 2
             

Interested in Tissue Regenix Group Ltd?
Register or log in to participate, create a watchlist, or set reminder

Company info

Tissue Regenix Group Ltd is a leading medical device company in regenerative medicine. The Company's patented decellularisation technology (dCELL®) removes DNA and other cellular material from animal and human soft tissue, leaving an acellular tissue scaffold that is not rejected by the patient's body and can be used to repair diseased or damaged body structures. Current applications address many crucial clinical needs in sports medicine, foot and ankle injuries, and wound care.

In August 2017, Tissue Regenix acquired CellRight Technologies®. This biotech company specialises in regenerative medicine and is dedicated to developing high-quality, innovative tissue scaffolds to enhance healing opportunities in defects created by trauma and disease. CellRight's human tissue products may be used in spine, trauma, general orthopaedic, dental and ophthalmological surgical procedures.

www.tissueregenix.com

Tissue Regenix Group Auction Details

The Ordinary Shares of Tissue Regenix Group Ltd were admitted to trading on Asset Match on 7 January 2025 at a price of 0.1 pence per share (being the equivalent to the CLN conversion).

Auctions are to be held quarterly and close at 4pm on the last Tuesday of each month (unless stated otherwise).

The tick size for this company is 0.01 pence per share.

Participants can send orders via their existing broker. Further details can be found by clicking on the "Auction instructions" section below.

Auction instructions

Buying and Selling Shares via Asset Match Private Market

To buy or sell shares in this company through the Asset Match Private Market, you will need to use a stockbroker.

If you already have an existing relationship with a UK broker on our approved broker list, you should be able to place an order to participate directly through them.

If you do not currently have a broker, please contact us and we will provide guidance on suitable options.

If you require assistance or have any questions about participating, please contact us:

📧 dealing@assetmatch.com

📞 +44 (0)20 7248 2788

Fees

When buying or selling shares, an Asset Match levy of 3% applies, with a minimum charge of £20 per trade (additional broker fees may also apply).

For more information on how the auction process works, please click here.

Key People

Jay

Jay LeCoque Executive Chairman

Jay has over 30 years of senior management experience focused on global healthcare diagnostics and clinical life sciences. Jay is the current CEO and Executive Chairman of Source BioScience since being appointed in 2017. He was an Executive Director of Bioquell plc from 2016 until its acquisition by ECOLAB in 2019. Prior to that, he was CEO of Celsis International plc from 2000 to 2009, and remained CEO following a public to private transaction in 2009 to form Celsis International Ltd until its acquisition in 2015.  Jay earned a BS in Business Administration and Marketing from Miami of Ohio University and his MBA from Northwestern University Kellogg School of Management.
   
Kirsten

Kirsten Lund CFO & Company Secretary

Kirsten Lund oversees all financial strategy, planning, and operations for Tissue Regenix. With more than 15 years of finance experience, she brings deep expertise in financial leadership and strategic business growth. Kirsten joined Tissue Regenix in 2010 and has progressed through several senior roles within the company. She served as Group Financial Controller for three years before being appointed Group Finance Director in November 2019, a position she held until January 2022. She then transitioned to EMEA Director, working closely with the management team to help drive the company’s strategic expansion into new markets. Drawing on her extensive experience in the healthcare sector, Kirsten provides invaluable insight into company structure and routes to market. Kirsten holds a Bachelor of Science degree from the University of Derby and achieved her ACCA qualification in 2015.
   
Judy

Judy Madden Chief Operating Officer

Judy has over 25 years of senior management experience in commercial and operations management in global life science companies. She held senior management roles at Charles River Laboratories from 2015 though 2024 including Executive Director of Celsis, and General Manager of Accugenix. Judy was Vice President, Corporate Development for Celsis international prior to its acquisition by Charles River in 2015. Prior to that she served in senior marketing and product development roles at medical device maker, Advanced Bionics. Judy holds a HBA degree in Marketing and Business Administration from Ivey Business School at Western University in London, Canada.